Genmab A/S (GMAB)
GMAB Stock Price Chart
Explore Genmab A/S interactive price chart. Choose custom timeframes to analyze GMAB price movements and trends.
GMAB Company Profile
Discover essential business fundamentals and corporate details for Genmab A/S (GMAB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
1 Jun 2009
Employees
2.64k
Website
https://www.genmab.comCEO
Jan van de Winkel
Description
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
GMAB Financial Timeline
Browse a chronological timeline of Genmab A/S corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is $0.35, while revenue estimate is $1.10bn.
Earnings released on 7 May 2026
EPS came in at $0.09 falling short of the estimated $0.15 by -42.00%, while revenue for the quarter reached $896.00m , missing expectations by -1.08%.
Earnings released on 17 Feb 2026
EPS came in at $0.05 falling short of the estimated $0.46 by -89.13%, while revenue for the quarter reached $1.06bn , missing expectations by -0.76%.
Earnings released on 6 Nov 2025
EPS came in at $0.65 surpassing the estimated $0.48 by +35.42%, while revenue for the quarter reached $1.02bn , beating expectations by +1.08%.
Earnings released on 7 Aug 2025
EPS came in at $0.54 surpassing the estimated $0.39 by +38.46%, while revenue for the quarter reached $924.81m , missing expectations by -2.91%.
Earnings released on 8 May 2025
EPS came in at $0.31 surpassing the estimated $0.23 by +34.78%, while revenue for the quarter reached $725.99m , missing expectations by -3.90%.
Earnings released on 12 Feb 2025
EPS came in at $0.57 surpassing the estimated $0.28 by +103.57%, while revenue for the quarter reached $891.43m , beating expectations by +12.57%.
Earnings released on 6 Nov 2024
EPS came in at $0.29 falling short of the estimated $0.35 by -17.14%, while revenue for the quarter reached $815.16m , beating expectations by +0.68%.
Earnings released on 8 Aug 2024
EPS came in at $0.22 falling short of the estimated $0.29 by -24.14%, while revenue for the quarter reached $777.83m , beating expectations by +14.48%.
Earnings released on 2 May 2024
EPS came in at $0.16 matching the estimated $0.16, while revenue for the quarter reached $594.93m , beating expectations by +12.08%.
Earnings released on 14 Feb 2024
EPS came in at $0.36 surpassing the estimated $0.34 by +5.88%, while revenue for the quarter reached $690.33m , beating expectations by +2.85%.
Earnings released on 7 Nov 2023
EPS came in at $0.47 falling short of the estimated $3.14 by -85.03%, while revenue for the quarter reached $669.38m , beating expectations by +4.13%.
Earnings released on 3 Aug 2023
EPS came in at $0.30 falling short of the estimated $2.18 by -86.24%, while revenue for the quarter reached $613.29m , beating expectations by +2.02%.
Earnings released on 10 May 2023
EPS came in at $0.05 falling short of the estimated $0.65 by -92.31%, while revenue for the quarter reached $416.08m , beating expectations by +2.92%.
Earnings released on 22 Feb 2023
EPS came in at $0.12 falling short of the estimated $3.15 by -96.19%, while revenue for the quarter reached $754.97m , beating expectations by +10.79%.
Earnings released on 9 Nov 2022
EPS came in at $0.53 falling short of the estimated $1.65 by -67.88%, while revenue for the quarter reached $535.64m , beating expectations by +13.13%.
Earnings released on 10 Aug 2022
EPS came in at $0.41 falling short of the estimated $1.55 by -73.55%, while revenue for the quarter reached $443.98m , beating expectations by +7.75%.
Earnings released on 11 May 2022
EPS came in at $0.11 falling short of the estimated $0.91 by -87.91%, while revenue for the quarter reached $315.14m , beating expectations by +4.88%.
Earnings released on 16 Feb 2022
EPS came in at $0.17 falling short of the estimated $5.30 by -96.79%, while revenue for the quarter reached $399.16m , beating expectations by +2.61%.
Earnings released on 10 Nov 2021
EPS came in at $0.21 surpassing the estimated $0.11 by +90.91%, while revenue for the quarter reached $360.41m , beating expectations by +33.31%.
Earnings released on 11 Aug 2021
EPS came in at $0.08 matching the estimated $0.08, while revenue for the quarter reached $314.36m , missing expectations by -11.02%.
GMAB Stock Performance
Access detailed GMAB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
